Non-melanoma primary skin cancer is the most common malignancy affecting man (White, 1992) , and the skin is also a frequent site of metastatic spread. Photodynamic therapy has been investigated as a new modality for the treatment of both primary and secondary skin cancer. This form of therapy uses a combination of photosensitiser, light and oxygen to kill tumour cells (Moan & Berg, 1992) . Haematoporphyrin derivative and its more purified successor Photofrin (P-II) are the sensitisers on which most clinical work has focused. For treatments using these sensitisers and superficial light illumination, complete response (CR) rates of 88% and 100% (Kennedy, 1983) have been reported for basal cell carcinomas (BCCs) . Similarly, Bowen's disease is reported to have a CR rate of 100% (Carruth & Williams, 1991; Jones et al., 1992) , and Gilson et al. (1988) have achieved CR rates of 74% for metastatic skin nodules from a variety of primary sites.
However, PDT using P-IT is associated with generalised skin photosensitivity which persists for up to 8-10 weeks following treatment (Dougherty et al., 1978) . During this period patients are advised to stay out of sunlight to avoid developing severe sunburn. In addition, Photofrin-based therapy may also cause significant damage to the normal tissues lying adjacent to the tumour. Consequently, such therapy cannot be considered ideal for the management of primary skin cancer, for which a number of other forms of treatment are available (e.g. excision, curettage, cautery, cryotherapy, topical chemotherapy or radiotherapy).
A new form of PDT which avoids the problem of generalised skin photosensitivity has recently been developed by Kennedy et al. (1990) . This utilises the biochemical pathway, present within every energy-producing cell in the body, whereby haem is synthesised from glycine and succinyl CoA. The direct precursor of haem in this pathway, protoporphyrin IX (PpIX), is thought to be the photosensitive species upon which the new technique depends. Studies of haem biosynthesis in the liver have indicated that the rate-limiting step in the pathway is the conversion of glycine and succinyl CoA to aminolaevulinic acid, and that this reaction is under negative-feedback control by haem. Subsequently, it has been shown that the systemic administration of excess exogenous ALA can bypass this control point in both mice (Divaris et al., 1990) and rats Loh et al., 1992) , with a number of tissues developing a fluorescence spectrum characteristic of PpIX and exhibiting histological damage after illumination. Similarly, applying ALA cream to skin cancers, but not normal undamaged skin, has been found to result in the development of PpIX fluorescence (White, 1992) . CR rates of 83%, 92% and 97% are reported respectively for treatment of Bowen's disease with surgery (Graham & Helwig, 1959) , topical 5-fluorouracil (Sturm, 1979) and superficial radiotherapy (Blank & Schnyder, 1985) . CR rates of 89.9%, 92.5% and 91.3% are reported for the treatment of BCCs with surgical excision, cryosurgery and radiotherapy respectively (Rowe et al., 1989) . For a new modality to become clinically acceptable it must possess distinct advantages over existing treatments.
Our results with Bowen's disease are encouraging. Many lesions are present in elderly patients with poorly vascularised skin, and are often in areas relatively intolerant of radiation such as the shin or ankle. This technique with ALA cream and superficial light illumination offers a single outpatient treatment and the reaction is mild. The vascularity of the skin is not limiting. Although the number of patients in our study is small, a light dose of 125 J cm2 seems adequate when combined with an interval of 3-5 h between cream and light.
Our results with basal cell carcinomas (BCCs) are poor. In their early report, Kennedy et al. (1990) quote a 90% CR for BCCs at a follow up of 2-3 months. A more recent paper (Kennedy & Pottier, 1992) gives a 3-month CR rate of 79%. Another study has also reported high initial CR rates for basal cell tumours (Wolf et al., 1993) , but the median followup was again short at 7 months. This present study reports longer follow-up results with a relatively high rate of relapse for BCCs. Reasons for these relapses may include insufficient penetration by either cream or light (or both). The light fluence needed for effective treatment is still the subject of speculation. At present little is known about the penetration of ALA cream through skin and tumours. Szeimies et al. (1992) with the epidermis. Thus, even the most superficial BCC is likely to possess cells deeper than the epidermis, a possible contributing factor towards the high relapse rate, given the requirement for penetration by both drug and then light.
It should, in the future, prove possible to monitor the distribution of PpIX fluorescence in skin tumours prior to treatment with light, using fluorescence microscopy of punch biopsies. We are currently investigating this possibility. It may also be possible to improve PpIX distribution and obtain dermal sensitisation by direct injection of ALA into the tumour. Repeated treatments may also improve results.
No reliable responses could be obtained with metastatic skin disease, nor was any fluorescence seen. It is likely that this may be because of inadequate penetration by the cream. This may be improved by the use of intra-tumour injections.
Kennedy's original work was carried out using filtered light from a slide projector . We chose to use 630 nm light from a laser as the absorption spectrum of protoporphyrin has a small peak at this wavelength (Pottier et al., 1986) . Although larger peaks are seen at shorter wavelengths, the penetration of light in such spectral regions is inferior, and absorption by haemoglobin is increased. However, it may be possible to use other light sources to treat skin tumours with topical ALA, and this would simplify the treatment considerably. Indeed, it has been established, at least in vitro, that irradiation of PpIX leads to its conversion to two isomers of protoporphyrin -A and B (Bonnett et al., 1980) . These isomers are in fact chlorins with a much increased and red-shifted absorption compared with PpIX. Consequently, as has been suggested by Charlesworth and Trusott (1993) , combined-wavelength irradiation (630 nm + 670 nm) may prove more effective than the singlewavelength treatment used in the present study.
We feel that our results with Bowen's disease are sufficiently encouraging for us to recommend its continuing use in patients, particularly those with large or multiple tumours which might be time-consuming and uncomfortable to treat by other means. However, further work is required to improve the results for BCCs, before ALA-based PDT becomes a viable alternative treatment for this condition.
